{
  "docId": "019de076-bff7-7739-a1e4-b124be2aa055",
  "docSlug": "9628ad2ef05910b50c9df1eb370993a9",
  "documentTitle": "argenx SE | Results Presentation Deck | 15 slides",
  "authorId": "argenx-se",
  "authorName": "argenx",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 15,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "comparison_table",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 1,
  "notes": "The slide uses a side-by-side comparison of two antibody mechanisms of action.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de076-bff7-7739-a1e4-b124be2aa055/6",
  "deckHref": "/decks/019de076-bff7-7739-a1e4-b124be2aa055",
  "deckJsonHref": "/decks/019de076-bff7-7739-a1e4-b124be2aa055.json",
  "deckAnchorHref": "/decks/019de076-bff7-7739-a1e4-b124be2aa055#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.06,
        "w": 0.4,
        "x": 0.55,
        "y": 0.52
      },
      "kind": "callout",
      "text": "Ph1b/2a in CMS and ALS to start in 2024",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "289262aa-2973-445c-9b28-971023b3b475",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.4,
        "x": 0.05,
        "y": 0.52
      },
      "kind": "callout",
      "text": "Full Phase 2 MMN data expected in 2024",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "372faf0e-6057-4f8c-b89b-668d0a16aa55",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.25,
        "x": 0.15,
        "y": 0.2
      },
      "kind": "image",
      "text": "Antibody diagram for Empasiprubart",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "30602c6a-e9a2-41c8-b532-d2ceeaf25aac",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.25,
        "x": 0.65,
        "y": 0.2
      },
      "kind": "image",
      "text": "Antibody diagram for ARGX-119",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "978dc059-f886-4485-92b9-7f017f9beef3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.15,
        "x": 0.55,
        "y": 0.62
      },
      "kind": "list",
      "text": "First-in-class MuSK agonist",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2290cf93-2951-421d-9af1-6c60935b96f4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.23,
        "x": 0.72,
        "y": 0.62
      },
      "kind": "list",
      "text": "Phase 1 study supports advancement into PoC studies",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "52875c36-6a98-4003-8426-68f6d5b564d6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.2,
        "x": 0.25,
        "y": 0.62
      },
      "kind": "list",
      "text": "91% reduction in need for IVIg rescue with empasiprubart in cohort 1",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5a9fb532-7539-4766-9cfc-767f487adc41",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.18,
        "x": 0.05,
        "y": 0.62
      },
      "kind": "list",
      "text": "Sweeping antibody targeting C2",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d6928ed8-8119-48ba-826e-261480fecb06",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.2,
        "y": 0.8
      },
      "kind": "paragraph",
      "text": "Natural history studies ongoing in both MMN and CMS to better understand real-world experience of patients",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5f00ad99-34ab-4d83-84ac-167f8da10c0a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.4,
        "x": 0.55,
        "y": 0.08
      },
      "kind": "title",
      "text": "ARGX-119 Enhancing the NMJ",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5c332500-bd1e-4270-b613-8009ffae03e5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.4,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "Empasiprubart Targeting Complement Upstream",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "875d6640-0128-43a2-a05f-3955b6b118d7",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Comparison frame",
      "slug": "comparison-frame",
      "agent": null,
      "layer": "slide",
      "matchId": "b9ddb049-a880-42b2-9323-64b84a21ab92",
      "evidence": "This slide compares data from natural history studies and clinical trials.",
      "confidence": 0.5
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 8,
      "from": 4,
      "beatId": "c590124e-9a42-4b81-beef-437126d71c96",
      "arcName": "Rags to Riches",
      "arcSlug": "rags-to-riches",
      "beatName": "Rising Success",
      "beatSlug": "rags-to-riches-rising-success",
      "evidence": "Presentation of pipeline growth, product net sales, and commercial execution",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}